The FY2025 (Dec) proxy of Editas Medicine names 20 peer companies for pay. Among Editas Medicine and these peers, CEO pay was 5th highest of 7 and total shareholder return was 6th highest of 7.
5th highest of 7in Editas Medicine and its pay peers, FY2025 (Dec) by CEO pay:
$2.2M$5.2M
6th highest of 7in Editas Medicine and its pay peers, FY2025 (Dec) by total shareholder return:
$10$202
Pay peer group, FY2025 (Dec) proxy
| Solid Biosciences | ||
| Lyell Immunopharma | ||
| Neurogene | ||
| Nkarta | ||
| Fate Therapeutics | ||
| Black Diamond Therapeutics | ||
| Adicet Bio, Inc. | Not disclosed | Not disclosed |
| Cabaletta Bio | Not disclosed | Not disclosed |
| Caribou Biosciences | Not disclosed | Not disclosed |
| Century Therapeutics | Not disclosed | Not disclosed |
| Generation Bio Co. | Not disclosed | Not disclosed |
| Lexeo Therapeutics | Not disclosed | Not disclosed |
| Passage Bio, Inc. | Not disclosed | Not disclosed |
| Precision BioSciences, Inc. | Not disclosed | Not disclosed |
| Prime Medicine | Not disclosed | Not disclosed |
| TScan Therapeutics, Inc. | Not disclosed | Not disclosed |
| Tenaya Therapeutics, Inc. | Not disclosed | Not disclosed |
| Verve Therapeutics, Inc. | Not disclosed | Not disclosed |
| Vor Biopharma | Not disclosed | Not disclosed |
| Voyager, Inc. | Not disclosed | Not disclosed |
20 companies
Changes by year
FY2023 (Dec) proxy
- AddedVerve Therapeutics, Inc.pay peer groupThe Compensation Committee also added Verve Therapeutics, Inc., a pre-clinical stage company, for being a locally-based, publicly traded company with a similar focus to us and with which
- RemovediQure N.V.pay peer groupdue to each of their market capitalizations now being outside of our desired range
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.